Background Limited information is available regarding factors associated with long‐term
drug survival of infliximab for psoriasis in real life. Objectives The main aim pf this study was …

Background Infiximab has been shown to be highly effective in phase III clinical trials, but
limited information is available regarding drug survival and maintenance of efficacy beyond …

Background Effective, fast‐acting and safe therapies are needed for long‐term maintenance
treatment of psoriasis. In October 2005, infliximab was approved for the treatment of …

Introduction Psoriasis is a chronic immune-mediated inflammatory skin disease that occurs
in 2.5–3.5% of the general population. Infliximab (INF), a TNF-α inhibitor biologic agent, is a …

Background Infliximab often requires dose escalation to maintain response. Studies
regarding long-term durability and dose escalation patterns for psoriasis are few. Objective …

Background Tumour necrosis factor‐α inhibitors, including infliximab (IFX), can improve
disease control of plaque‐type psoriasis. Objectives The Real‐World Assessment of Long …

Abstract Background/Aims: Infliximab has been approved for the treatment of chronic plaque
psoriasis for only a few years. As physicians gain confidence in initiating and maintaining …

Background Adherence to treatment is an indicator of treatment success. Long‐term data on
adherence to biologic treatment in psoriasis are lacking. Objectives To compare the tumour …

Background Despite the chronicity of psoriasis, most systematic reviews focus on short‐term
treatment. Methods The systematic search strategy and results from the German Psoriasis …

Background Infliximab, a mouse–human chimeric monoclonal antibody directed against
tumour necrosis factor‐α, has been shown to be effective for moderate to severe psoriasis …